Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The group has obtained the drug production registration approval for vitamin K1 injection (1ml: 10mg) from the China National Drug Administration. It is a Class 3 chemical drug, which is deemed to have passed the consistency evaluation.

Vitamin K1 injections are mainly used to treat bleeding due to vitamin K deficiency and prevent vitamin K deficiency that cannot be obtained through nutritional supplementation. Vitamin K1 injection is a basic clinical drug. It is widely used for bleeding prevention and first aid, and the market is huge. The approval of this product has enriched the Group's injectable product portfolio.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.